A packaging problem has led Merck to recall 276,000 bottles of a cancer med because the child-proof feature can fail, allowing children to get their hands on the chemo drug.
Australia's Therapeutic Good Administration has registered mAb biosimilar Inflectra (infliximab) from Hospira, the company said in a press release, noting it sets the stage for reimbursement under the country's Pharmaceutical Benefits Scheme.
Merck & Co.'s plant in Pennsylvania has been impacted by the drugmaker's drastic job cuts in the last 5 years, losing hundreds of manufacturing jobs. Now, in an email exchange made public by one of the unions there, a labor official has lashed out at CEO Ken Frazier, saying workers are now forced to work 16-hours shifts, the fatigue from which puts themselves and others in danger.
Merck & Co.'s CEO Kenneth Frazier thought he was doing a good thing when he announced that employees would get an extra day off in appreciation for their hard work. But the fact that union employees are not getting the extra time at the Labor Day holiday has led one union official to publicly lash out at Merck and Frazier.
Merck's Januvia has seen its fair share of competition from generics makers and other diabetes challengers. But now, it could face a new rival on the scene--and it's a device.
Merck & Co. has encountered a few roadblocks in recent years with its diabetes drug, Januvia as safety concerns took a bite out of sales. The company has worked hard to reverse this trend, and recently unveiled data on heart safety could do its part. But now Merck could be facing another threat, and not from a regulator or competing drugmaker--but a devicemaker.
Merck & Co.'s Keytruda has jumped on the FDA's priority review track for a new first-line use in melanoma. The PD-1 immunotherapy, already approved to treat relapsed melanoma and under FDA review in lung cancer, needs the broader melanoma approval to keep abreast of Bristol-Myers Squibb's rival drug Opdivo.
The job cuts at Merck have been massive ever since its 2009 merger with Schering-Plough, 36,000 in 5 years. They have almost run their course, but manufacturing will make up most of what is left as it continues to shed manufacturing plants.
Merck Animal Health launched its Fortegra vaccine in South America to help combat a parasitic disease that strikes at the intestinal tract of broilers.
The good news for Merck & Co.'s far-flung workforce: The job cuts hanging over your heads for the past five years are almost finished. The not-so-good news: Several thousand payroll reductions are yet to come.